No connection

Search Results

AMPH vs TBPH

AMPH
Amphastar Pharmaceuticals, Inc.
BEARISH
Price
$18.18
Market Cap
$835.4M
Sector
Healthcare
AI Confidence
85%
TBPH
Theravance Biopharma, Inc.
NEUTRAL
Price
$16.72
Market Cap
$861.0M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AMPH
8.96
TBPH
8.12
Forward P/E
AMPH
5.21
TBPH
12.34
P/B Ratio
AMPH
1.05
TBPH
2.88
P/S Ratio
AMPH
1.16
TBPH
8.01
EV/EBITDA
AMPH
5.44
TBPH
-297.73

Profitability

Gross Margin
AMPH
49.46%
TBPH
65.19%
Operating Margin
AMPH
19.45%
TBPH
43.6%
Profit Margin
AMPH
13.63%
TBPH
98.54%
ROE
AMPH
12.9%
TBPH
44.84%
ROA
AMPH
6.37%
TBPH
-0.54%

Growth

Revenue Growth
AMPH
-1.8%
TBPH
144.7%
Earnings Growth
AMPH
-31.0%
TBPH
--

Financial Health

Debt/Equity
AMPH
0.83
TBPH
0.14
Current Ratio
AMPH
4.02
TBPH
10.93
Quick Ratio
AMPH
2.8
TBPH
10.73

Dividends

Dividend Yield
AMPH
--
TBPH
--
Payout Ratio
AMPH
0.0%
TBPH
0.0%

AI Verdict

AMPH BEARISH

AMPH exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and financial stability, though the absence of an Altman Z-Score raises concern about default risk. The stock trades at a discount to its Graham Number ($28.09) and intrinsic value ($14.21), suggesting undervaluation on a defensive basis. However, this is overshadowed by deteriorating fundamentals: negative revenue and earnings growth (YoY -1.8% and -31.0%), declining quarterly earnings, and a significant 36.4% drop in price over the past month. Insider selling activity further undermines confidence, with $0.95M in sales over six months despite no buy activity.

Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational efficiency
Graham Number of $28.09 suggests defensive undervaluation relative to intrinsic safety margin
High gross margin (49.46%) and operating margin (19.45%) reflect strong pricing power and cost control
Risks
Negative year-over-year earnings growth (-31.0%) and revenue decline (-1.8%) indicate deteriorating business momentum
Recent insider selling of $0.95M over six months signals potential lack of confidence from management
Stock has declined 36.4% in one month and 51.1% over three years, reflecting prolonged underperformance
TBPH NEUTRAL

TBPH presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation trading very close to its Graham Number ($16.41) and Intrinsic Value ($14.42). While the company exhibits explosive revenue growth (144.7% YoY) and an exceptionally strong liquidity position (Current Ratio 10.93), these fundamentals are countered by bearish insider sentiment and a negative technical trend. The current price of $16.72 suggests the stock is fully valued based on deterministic models, leaving little margin of safety despite the low P/E ratio.

Strengths
Explosive YoY revenue growth of 144.70%
Exceptional liquidity with a Current Ratio of 10.93
Very low leverage with a Debt/Equity ratio of 0.14
Risks
Strongly bearish insider activity with 5 sell transactions and 0 buys
Bearish technical trend (0/100 score)
Highly volatile quarterly earnings track record with frequent misses

Compare Another Pair

AMPH vs TBPH: Head-to-Head Comparison

This page compares Amphastar Pharmaceuticals, Inc. (AMPH) and Theravance Biopharma, Inc. (TBPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile